Two medical practitioners and co-founders of Fullerton Healthcare Corporation faced substantial financial penalties on Friday for their involvement in a scheme to falsify entertainment expense claims that inflated costs by more than S$211,000. Daniel Chan Pai Sheng and Michael Tan Kim Song, both 52 years old, received fines totalling S$160,000 following guilty pleas, marking a significant outcome in a corporate fraud investigation that has ensnared multiple senior executives of the private healthcare investment group.
The falsified claims did not translate into personal profit for either man. Court documents reveal that the inflated sums were channelled to benefit Collin Chiew, a 58-year-old executive who previously served as chief executive of insurance broker Aon Singapore from January 2015 through July 2018. Chiew's own legal proceedings remain ongoing, and investigators have not publicly disclosed whether he received the full amount in question.
Chan pleaded guilty to five counts of account falsification on July 8, resulting in a fine of S$135,000. His charges were connected to entertainment claims initially valued at over S$336,000, though actual expenditures totalled approximately S$125,000. This discrepancy of S$211,000 represents a substantial degree of misrepresentation. Tan's culpability was narrower in scope—he pleaded guilty to a single count of falsification and received a fine of S$25,000. His charge involved a single false claim approximately S$82,000 in stated value against actual expenses exceeding S$42,000, creating an inflated amount of nearly S$40,000 that formed part of the broader scheme.
The prosecution initially pursued graft-related charges against both men, reflecting suspicions that the scheme may have involved corruption. However, prosecutors exercised discretionary authority to seek a discharge not amounting to acquittal for all corruption allegations against Chan and Tan. District Judge Paul Quan approved this application on July 10. This procedural outcome is significant because individuals granted such discharges remain vulnerable to future prosecution should fresh evidence or information emerge, though no active prosecution currently applies to those charges.
The Fullerton Healthcare case extends beyond these two individuals. In August 2025, David Sin, a 47-year-old third co-founder, pleaded guilty to six counts of falsifying accounts and received an identical fine of S$160,000. Sin's involvement appears to have been instrumental in the scheme's mechanics, as court documents indicate he directly participated in obtaining false receipts and facilitating the provision of inflated documentation to support the false claims.
The investigation revealed an elaborate operational structure spanning multiple jurisdictions. Tan maintained a directorship at Fullerton Healthcare Group, a subsidiary providing healthcare services through a network of physicians and specialists while assisting clients with insurance claim processing. Chan held the position of president at Fullerton Health China, another FHC subsidiary. Both men have since relinquished these roles. Fullerton Healthcare Corporation itself operated as an investment holding company coordinating these diverse medical and administrative operations.
The scheme's origins trace to 2015, when Chiew approached Chan requesting financial assistance for personal purposes including children's expenses and housing costs. Chan subsequently discussed Chiew's request with Tan, and the two eventually devised a system to funnel money through fabricated business entertainment expenses. Beginning in 2015, Chan commenced regular business travel to Hong Kong, visiting approximately twice monthly to support FHC operations. Before each journey, he would instruct Sin to arrange inflated or entirely fictional Karaoke bar receipts, with another conspirator, Tei Chu Pink, 46, preparing the fraudulent documentation.
During these Hong Kong excursions, Chan participated in actual visits to KTV establishments alongside Sin and Tei, sometimes meeting with prospective investors. After collecting the inflated receipts from Tei, Chan would arrange their delivery to designated individuals within FHC or Fullerton Health China who would process them as legitimate business expenses. In numerous instances, Chan paid substantially lesser amounts at the venues through personal cash or credit arrangements—sometimes making no payment whatsoever—yet submitted inflated receipts to the company. This systematic underreporting of actual costs against submitted claims produced the documented shortfalls.
Tan's involvement extended to direct participation in at least one coordinated conspiracy. In 2016, Tan, Chan, and Sin collectively engaged in falsifying an entertainment claim, demonstrating that the scheme involved deliberate coordination among multiple executives rather than isolated instances of misconduct. Court documents confirmed that various false claims proceeded with Tan's explicit knowledge, establishing his role as an active participant rather than a passive bystander.
The case carries particular significance for Malaysian and regional business communities, as it demonstrates how private healthcare enterprises structured across multiple subsidiaries in different jurisdictions can become vehicles for sophisticated financial manipulation. The involvement of insurance-related professionals and the crossing of international borders in Singapore, Hong Kong, and China illustrate how such schemes can exploit gaps in oversight when executives operate across diverse corporate entities and countries.
For Malaysian investors and healthcare sector participants, this prosecution underscores the critical importance of robust internal financial controls, transparent expense reporting mechanisms, and independent audit functions. The penalties imposed—totalling S$160,000 across three executives—represent substantial consequences but may serve as modest deterrents given the scale of falsification involved. The fact that the false claims exceeded S$211,000 while fines totalled only S$160,000 raises questions about proportionality in sentencing and corporate accountability frameworks.
The procedural aspects of the case, particularly the discharge of graft charges, reflect prosecutorial strategy balancing conviction certainty against broader investigation objectives. This approach suggests that authorities may have prioritized securing guilty pleas on falsification charges with clear evidence while retaining optionality regarding corruption allegations that might have required more complex proof. For Malaysian regulators monitoring corporate governance standards in the healthcare and insurance sectors, the case illustrates how financial fraud can persist within apparently legitimate business structures unless subjected to rigorous oversight and audit scrutiny.
